Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer

European Urology

Volumn 39, Issue 2, 2001, Pages 138-144

  Aaltomaa, Sirpa ^a   Lipponen, P ^b   Ala Opas, M ^a   Kosma, V M ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

CD44 standard; CD44v3; CD44v6; Prognosis; Prostate cancer

Indexed keywords

CD44V ANTIGEN; HERMES ANTIGEN; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANTIGENS, CD44; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS;

EID: 0035101493     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052428     Document Type: Article

References (23)

1. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer
2. Aberrant E-cadherin and alphacatenin expression in prostate cancer: Correlation with patient survival
3. Mitotic activity and prognosis in prostatic adenocarcinoma
4. CD44 is a metastasis supressor gene for prostatic cancer located on human chromosome 11p13
5. The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation
6. Involvement of CD44 and its variant isoforms in membranecytoskeleton interaction, cell adhesion and tumour metastasis
7. Metastasis supression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate
8. CD44 and CD44v6 downregulation in clinical prostate carcinoma: Relation to Gleason grade and cytoarchitecture
9. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumour grade and ploidy
10. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy
11. Altered expression of CD44 in human prostate cancer during progression
12. Histologic grading and clinical staging of prostatic carcinoma
13. Histological grade, perineural infiltration, tumor-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma
14. Progression and survival in prostatic adenocarcinoma: A comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy
15. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis
16. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long term follow-up
17. Expression of CD44 in prostate cancer cells: Association with cell proliferation and invasive potential
18. Expression of cyclin A and D proteins in prostate cancer and their relation to clinicopathological variables and patient survival
19. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma
20. The prognostic significance of proliferation-associated protein p120 expression in prostate adenocarcinoma: A comparison with cyclins A and B1, Ki-67. Proliferating cell nuclear antigen, and p34cdc2
21. Adhesion in leucocyte homing and differentiation
22. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy